Omeprazol Evolan (Omeprazole)

Omeprazole, the active ingredient in Omeprazol Evolan, is a proton pump inhibitor presented as an oral dosage form for oral use. It reduces gastric acid production and is employed in the management of gastro‑esophageal reflux disease, peptic ulcer disease, and related acid‑related conditions in adult patients.\n\nGNH India supplies Omeprazol Evolan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, transplant centres and oncology clinics worldwide, ensuring quality and regulatory compliance across markets.

Omeprazole is a proton pump inhibitor used to manage conditions associated with excess gastric acid secretion.\n\nGastro‑esophageal reflux disease (GERD): reduces acid reflux symptoms and promotes healing of esophageal irritation.\nPeptic ulcer disease: facilitates ulcer healing by suppressing gastric acid production.\nNSAID‑induced ulcer prophylaxis: prevents ulcer formation in patients receiving non‑steroidal anti‑inflammatory drugs.\nHelicobacter pylori eradication (in combination therapy): enhances the effectiveness of antibiotic regimens by creating a less acidic gastric environment.\nAcid‑related dyspepsia: alleviates indigestion symptoms caused by excess gastric acid.

Omeprazole is generally well tolerated, but adverse reactions may occur.\n\nCommon Side Effects:\n- Headache: mild, transient headache reported in some patients.\n- Diarrhea: loose stools or increased frequency of bowel movements.\n- Nausea: occasional feeling of queasiness, usually mild.\n- Abdominal pain: mild discomfort in the stomach area.\n- Flatulence: increased gas production leading to bloating.\n\nSerious or Rare Side Effects:\n- Clostridioides difficile infection: rare but severe colitis associated with altered gut flora, may cause watery diarrhea.\n- Hypomagnesemia: low magnesium levels with prolonged use, can lead to muscle cramps, tremors, or cardiac arrhythmias.\n- Acute interstitial nephritis: rare kidney inflammation presenting with reduced urine output, swelling, or elevated creatinine.\n- Fracture risk: long‑term therapy may be associated with increased incidence of bone fractures, especially in the hip, wrist, or spine.

When prescribing omeprazole, clinicians should consider several precautionary measures to ensure safe use.\n\nAssess renal function: evaluate kidney status and adjust therapy in severe impairment.\nMonitor magnesium: check serum magnesium levels during prolonged treatment to avoid deficiency.\nAvoid abrupt discontinuation: sudden stop may cause rebound acid hypersecretion and symptom recurrence.\nUse with caution in hepatic disease: limited data for patients with severe liver dysfunction.\nPregnancy and lactation: evaluate risk‑benefit before prescribing to pregnant or breastfeeding women.\nStore at ambient temperature: keep in the original pack, protect from moisture and light.

Omeprazole may alter the pharmacokinetics of several medicines, leading to clinically relevant interactions.\n\nMajor Interactions (Avoid):\n- Clopidogrel: omeprazole reduces its antiplatelet activation, potentially decreasing efficacy.\n- Atazanavir: decreased absorption of this protease inhibitor when co‑administered, compromising HIV treatment.\n- Ketoconazole: reduced absorption when taken with omeprazole, may diminish antifungal effect.\n\nModerate Interactions (Monitor Closely):\n- Warfarin: omeprazole may increase INR; monitor coagulation parameters regularly.\n- Digoxin: higher serum levels reported; check cardiac function and drug levels as needed.\n- Methotrexate: high-dose therapy may raise methotrexate concentrations; monitor renal function and drug levels.\n- Phenytoin: omeprazole may increase phenytoin levels; monitor for toxicity.\n- Ciclosporin: omeprazole can raise ciclosporin concentrations; monitor renal function and drug levels.